
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1736115/publications.pdf Version: 2024-02-01



FRIC D HSI

#	Article	IF	CITATIONS
1	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	2.5	1
2	Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study. American Journal of Clinical Pathology, 2022, 157, 578-585.	0.7	5
3	Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2022, 146, 351-359.	2.5	5
4	Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. Journal of Clinical Pathology, 2022, 75, 636-642.	2.0	2
5	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Modern Pathology, 2022, 35, 306-318.	5.5	16
6	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	7.0	22
7	Analysis of clinical and serologic predictors of response to extracorporeal photopheresis therapy in cutaneous T ell lymphoma patients. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 600-603.	1.5	0
8	Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology, 2022, 35, 1411-1422.	5.5	11
9	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
10	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia, 2021, 35, 1023-1036.	7.2	62
11	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	5.5	9
12	Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. Human Pathology, 2021, 107, 1-8.	2.0	2
13	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood, 2021, 137, 3685-3689.	1.4	50
14	A Tissue Counterpart to Monoclonal B-Cell Lymphocytosis. Archives of Pathology and Laboratory Medicine, 2021, 145, 1544-1551.	2.5	4
15	Characterization of DLBCL with a PMBL gene expression signature. Blood, 2021, 138, 136-148.	1.4	19
16	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
17	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti–CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	3.7	10
18	Impact of next generation sequencing results on clinical management in patients with hematological disorders. Leukemia and Lymphoma, 2021, 62, 1702-1710.	1.3	4

#	Article	IF	CITATIONS
19	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
20	Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. Blood, 2021, 138, 2398-2398.	1.4	0
21	Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. Survey of Ophthalmology, 2020, 65, 361-370.	4.0	10
22	Endobronchial pseudocarcinomatous hyperplasia mimicking squamous cell carcinoma associated with primary pulmonary ALKâ€negative anaplastic large cell lymphoma. Histopathology, 2020, 76, 781-784.	2.9	1
23	Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. American Journal of Surgical Pathology, 2020, 44, e1-e14.	3.7	13
24	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia, 2020, 34, 1646-1657.	7.2	54
25	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Annals of Diagnostic Pathology, 2020, 49, 151623.	1.3	8
26	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
27	Inhibition of cyclinâ€dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. EJHaem, 2020, 1, 161-169.	1.0	2
28	Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica, 2020, 105, 1895-1906.	3.5	46
29	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	1.3	1
30	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood, 2020, 135, 2224-2234.	1.4	62
31	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp> /Alliance 50403. American Journal of Hematology, 2020, 95, 583-593.	4.1	18
32	Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discovery, 2020, 10, 1267-1281.	9.4	40
33	Chronic active Epsteinâ€Barr virus infection: A heterogeneous entity requiring a high index of suspicion for diagnosis. International Journal of Laboratory Hematology, 2020, 42, 99-106.	1.3	3
34	Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas. American Journal of Clinical Pathology, 2020, 153, 646-655.	0.7	9
35	Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808.	4.1	26
36	Extranodal Marginal Zone Lymphoma of the Central Nervous System Includes Parenchymal-Based Cases With Characteristic Features. American Journal of Clinical Pathology, 2020, 154, 124-132.	0.7	11

#	Article	IF	CITATIONS
37	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422.	1.3	21
38	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Research, 2020, 80, 2031-2044.	0.9	36
39	Gene Expression and Epigenetic Analysis in Relapsed/Refractory Diffuse Large B Cell Lymphoma Provides Insights into Evolution of Treatment Resistance to R-CHOP. Blood, 2020, 136, 26-26.	1.4	1
40	Integrative DNA Methylation and Gene Expression Analysis Reveals Candidate Biomarkers Associated with Dichotomized Response to Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 22-22.	1.4	0
41	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. Blood, 2020, 136, 21-21.	1.4	0
42	SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. British Journal of Haematology, 2019, 185, 145-147.	2.5	9
43	<i><scp>JAK</scp>2</i> double minutes with resultant simultaneous amplification of <i><scp>JAK</scp>2</i> and <i><scp>CD</scp>274</i> in a therapyâ€related myelodysplastic syndrome evolving into an acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 566-570.	2.5	5
44	Composite chronic myeloid leukemia and essential thrombocythemia with <i>BCRâ€ABL1</i> fusion and <i>CALR</i> mutation. American Journal of Hematology, 2019, 94, 504-505.	4.1	9
45	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. Nature Communications, 2019, 10, 5061.	12.8	18
46	The whole-genome landscape of Burkitt lymphoma subtypes. Blood, 2019, 134, 1598-1607.	1.4	113
47	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	5.5	39
48	The role of autologous stem cell transplantation in patients with nodal peripheral Tâ€cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer, 2019, 125, 1507-1517.	4.1	106
49	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with highâ€risk follicular lymphoma: CALGB 50904 (Alliance). Cancer, 2019, 125, 3378-3389.	4.1	10
50	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	5.5	25
51	Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Advances, 2019, 3, 132-135.	5.2	15
52	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death and Disease, 2019, 10, 924.	6.3	51
53	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	5.5	50
54	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. Blood, 2019, 134, 5092-5092.	1.4	1

#	Article	IF	CITATIONS
55	Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning. Blood, 2019, 134, 2891-2891.	1.4	1
56	Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab. Blood, 2019, 134, 1515-1515.	1.4	0
57	Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 1499-1499.	1.4	1
58	Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. Blood, 2019, 134, 1572-1572.	1.4	0
59	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. Blood, 2019, 134, 19-19.	1.4	4
60	Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. Therapeutic Advances in Hematology, 2018, 9, 81-87.	2.5	4
61	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880.	5.5	3
62	Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology, 2018, 31, 690-704.	5.5	35
63	<i>MYD88</i> L265P Mutation in Lymphoid Malignancies. Cancer Research, 2018, 78, 2457-2462.	0.9	92
64	Ocular/adnexal lymphoma: dissimilar to systemic lymphoma. Survey of Ophthalmology, 2018, 63, 381-388.	4.0	13
65	Diffuse Aggressive B-Cell Lymphomas. , 2018, , 271-305.e5.		0
66	Intensive immunochemotherapy for high-risk aggressive B-cell lymphomas: MYC-rearrangements and beyond. Lancet Haematology,the, 2018, 5, e600-e601.	4.6	0
67	CLTO30, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Advances, 2018, 2, 1738-1749.	5.2	56
68	<i>JAK2</i> V617Fâ€positive acute myeloid leukaemia (AML): a comparison between <i>de novo</i> AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	2.5	22
69	Long-Term Follow-up of SWOC S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. Blood, 2018, 132, 929-929.	1.4	6
70	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. Blood, 2018, 132, 2927-2927.	1.4	2
71	Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 1692-1692.	1.4	1
72	Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study. Blood, 2018, 132, 397-397.	1.4	6

#	Article	IF	CITATIONS
73	B-Cell Leukemias of Mature Lymphocytes. , 2018, , 397-413.e2.		0
74	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. Blood, 2018, 132, 2270-2270.	1.4	0
75	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878.	1.4	0
76	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	1.4	0
77	The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discovery, 2017, 7, 369-379.	9.4	163
78	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 193-200.	0.4	27
79	NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Modern Pathology, 2017, 30, 854-876.	5.5	15
80	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. Journal of Experimental Medicine, 2017, 214, 1371-1386.	8.5	144
81	Assessment of semiâ€quantitative grading of red blood cell abnormalities utilizing images from the CellaVision <scp>DM</scp> 96 compared to manual light microscopy. International Journal of Laboratory Hematology, 2017, 39, e110-e112.	1.3	2
82	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	3.5	62
83	2016 WHO Classification update—What's new in lymphoid neoplasms. International Journal of Laboratory Hematology, 2017, 39, 14-22.	1.3	16
84	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. Cancer, 2017, 123, 1174-1183.	4.1	51
85	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	3.8	39
86	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgB <sup>-</sup> chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	T /Overloc 5.5	k 10 Tf 50 2 52
87	Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). International Journal of Laboratory Hematology, 2017, 39, 409-417.	1.3	12
88	Genetic and Functional Drivers of Diffuse Large BÂCell Lymphoma. Cell, 2017, 171, 481-494.e15.	28.9	804
89	A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of Oncology, 2017, 28, 2806-2812.	1.2	72
90	Orbital diffuse large B-cell lymphoma with combined variable immunodeficiency. Orbit, 2017, 36, 340-343.	0.8	3

#	Article	IF	CITATIONS
91	Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 797-803.	0.4	15
92	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.7	6
93	CATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. Journal of Clinical Investigation, 2017, 127, 3527-3542.	8.2	35
94	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	1.8	26
95	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. American Journal of Surgical Pathology, 2016, 40, 36-43.	3.7	103
96	Clinical approach to diffuse large B cell lymphoma. Blood Reviews, 2016, 30, 477-491.	5.7	26
97	Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. Journal of the National Cancer Institute, 2016, 108, djw131.	6.3	37
98	Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. American Journal of Surgical Pathology, 2016, 40, 335-341.	3.7	53
99	General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute, 2016, 108, djw250.	6.3	2
100	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 2484-2492.	1.6	106
101	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
102	Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Human Pathology, 2016, 52, 173-178.	2.0	5
103	T-cell Lymphomas. Surgical Pathology Clinics, 2016, 9, 131-141.	1.7	12
104	CAL2 Immunohistochemical Staining Accurately Identifies <i>CALR</i> Mutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2016, 146, 431-438.	0.7	17
105	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 1640-1648.	1.3	12
106	Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Leukemia and Lymphoma, 2016, 57, 212-215.	1.3	6
107	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. Blood, 2016, 128, 1087-1087.	1.4	4
108	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood, 2016, 128, 469-469.	1.4	79

#	Article	IF	CITATIONS
109	Acquired resistance to venetoclax (ABT-199) in <i>t(14;18)</i> positive lymphoma cells. Oncotarget, 2016, 7, 70000-70010.	1.8	59
110	CCMCL1: a new model of aggressive mantle cell lymphoma. Blood, 2015, 125, 2730-2732.	1.4	17
111	Update in large cell lymphoma: understanding the pathology report. Hematology American Society of Hematology Education Program, 2015, 2015, 605-617.	2.5	3
112	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death and Disease, 2015, 6, e1593-e1593.	6.3	292
113	Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia, 2015, 29, 1857-1867.	7.2	32
114	Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery. Cancer Treatment and Research, 2015, 165, 27-50.	0.5	10
115	T-Lymphoblastic Leukemia/Lymphoma. American Journal of Clinical Pathology, 2015, 144, 411-422.	0.7	105
116	PRPF8 defects cause missplicing in myeloid malignancies. Leukemia, 2015, 29, 126-136.	7.2	102
117	Combination of ibrutinib with <scp>ABT</scp> â€199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of <scp>BTK</scp> , <scp> AKT</scp> and <scp>BCL</scp> 2 pathways. British Journal of Haematology, 2015, 168, 765-768.	2.5	75
118	Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). Blood, 2015, 126, 2741-2741.	1.4	3
119	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	1.4	23
120	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
121	Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers. Journal of Clinical Pathology, 2014, 67, 1093-1098.	2.0	8
122	IgG4+ Plasma Cells in Isolated Reactive Lymphadenopathy. American Journal of Clinical Pathology, 2014, 142, 432-434.	0.7	2
123	Flow cytometry in cerebrospinal fluid—Rational use of laboratory services. American Journal of Hematology, 2014, 89, 941-942.	4.1	2
124	Molecular subtype classification of formalinâ€fixed, paraffinâ€embedded diffuse large Bâ€cell lymphoma samples on the <scp>ICEP</scp> lex <sup>®</sup> system. British Journal of Haematology, 2014, 167, 281-285.	2.5	16
125	Flow Cytometric Analysis of Cerebrospinal Fluid Has Low Diagnostic Yield in Samples Without Atypical Morphology or Prior History of Hematologic Malignancy. American Journal of Clinical Pathology, 2014, 141, 515-521.	0.7	11
126	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. American Journal of Surgical Pathology, 2014, 38, 768-775.	3.7	44

#	Article	IF	CITATIONS
127	Indolent mantle cell lymphoma. Leukemia and Lymphoma, 2014, 55, 761-767.	1.3	33
128	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	1.4	192
129	Prevalence and Clinical Implications of Epstein–Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	7.0	117
130	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	5.5	112
131	PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Haematologica, 2014, 99, e148-e151.	3.5	29
132	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 2014, 124, 1473-1480.	1.4	401
133	The SOX11-PDGFA axis in mantle cell lymphoma. Blood, 2014, 124, 2165-2166.	1.4	3
134	Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial. Blood, 2014, 124, 978-978.	1.4	3
135	CNS Lymphoma. , 2014, , 207-223.		Ο
136	Mantle Cell Lymphoma. , 2014, , 277-302.		0
137	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 864-864.	1.4	1
138	Undiagnosed mycosis fungoides with transformation to large cell peripheral T-cell lymphoma. Clinical Advances in Hematology and Oncology, 2014, 12, 6-11.	0.3	0
139	Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surgical Pathology Clinics, 2013, 6, 677-692.	1.7	2
140	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
141	Lymphomas of the Gastrointestinal Tract. Surgical Pathology Clinics, 2013, 6, 405-424.	1.7	2
142	Chromosomal Rearrangements of 6p25.3 Define a New Subtype of Lymphomatoid Papulosis. American Journal of Surgical Pathology, 2013, 37, 1173-1181.	3.7	182
143	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer, 2013, 119, 3797-3804.	4.1	47
144	The phosphatidylinositol 3â€kinases ( <scp>PI</scp> 3 <scp>K</scp> ) inhibitor <scp>GS</scp> â€1101 synergistically potentiates histone deacetylase inhibitorâ€induced proliferation inhibition and apoptosis through the inactivation of <scp>PI</scp> 3 <scp>K</scp> and extracellular signalâ€regulated kinase pathways. British Journal of Haematology, 2013, 163, 72-80.	2.5	28

#	Article	IF	CITATIONS
145	Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1398-1403.	7.1	494
146	Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality. Blood, 2013, 122, 2596-2596.	1.4	1
147	PRPF8 Defects Cause Missplicing In Myeloid Malignancies. Blood, 2013, 122, 2838-2838.	1.4	1
148	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. Blood, 2013, 122, 3029-3029.	1.4	8
149	CD30 Immunohistochemical Expression In Diffuse Large B-Cell Lymphoma Is Associated With Decreased Overall Survival and The Non-Germinal Center Molecular Subtype. Blood, 2013, 122, 4318-4318.	1.4	12
150	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	1.4	3
151	Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model. Blood, 2013, 122, 645-645.	1.4	2
152	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	1.4	1
153	The Genetic Landscape Of Mantle Cell Lymphoma and The Epigenetic Origins Of Lineage Specific Mutations. Blood, 2013, 122, 347-347.	1.4	0
154	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 363-363.	1.4	0
155	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	1.4	0
156	Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma. Blood, 2013, 122, 842-842.	1.4	18
157	Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica, 2012, 97, 579-585.	3.5	72
158	Cyclin D1-negative Blastoid Mantle Cell Lymphoma Identified by SOX11 Expression. American Journal of Surgical Pathology, 2012, 36, 214-219.	3.7	65
159	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood, 2012, 120, 3048-3057.	1.4	360
160	The genetic landscape of mutations in Burkitt lymphoma. Nature Genetics, 2012, 44, 1321-1325.	21.4	517
161	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	7.2	301
162	Pathologic and Molecular Genetic Features of Chronic Lymphocytic Leukemia. Seminars in Oncology, 2012, 39, 74-79.	2.2	14

#	Article	IF	CITATIONS
163	Diffuse Aggressive B-Cell Lymphomas. , 2012, , 261-292.		1
164	Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment. Blood, 2012, 120, 1614-1614.	1.4	7
165	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. Blood, 2012, 120, 1696-1696.	1.4	3
166	Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry. Blood, 2012, 120, 4263-4263.	1.4	9
167	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 544-544.	1.4	1
168	B-Cell Leukemias of Mature Lymphocytes. , 2012, , 387-402.		1
169	A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood, 2012, 120, 5045-5045.	1.4	0
170	Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations. Blood, 2012, 120, 777-777.	1.4	1
171	Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the Iceplex® System Blood, 2012, 120, 2705-2705.	1.4	0
172	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2012, 120, 3595-3595.	1.4	1
173	Hematogones Contained in CD34+ Apheresis Products for Hematopoietic Progenitor Cell Transplantation Have No Adverse Impact On Engraftment Outcomes Blood, 2012, 120, 3022-3022.	1.4	3
174	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
175	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	1.4	0
176	BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). Blood, 2012, 120, 301-301.	1.4	0
177	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. Blood, 2012, 120, 898-898.	1.4	0
178	Microenvironment in peripheral T cell lymphomas: macrophages and angiogenesis as targets. Leukemia and Lymphoma, 2011, 52, 3-4.	1.3	0
179	Selection and Validation of Antibodies for Signal Transduction Immunohistochemistry. Methods in Molecular Biology, 2011, 717, 45-53.	0.9	0
180	Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Human Pathology, 2011, 42, 552-557.	2.0	99

#	Article	IF	CITATIONS
181	Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica, 2011, 96, 1121-1127.	3.5	171
182	HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 914-923.	4.9	13
183	Plasmablastic Lymphoma and Related Disorders. American Journal of Clinical Pathology, 2011, 136, 183-194.	0.7	117
184	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Modern Pathology, 2011, 24, 596-605.	5.5	178
185	Phosphoproteins and the Dawn of Functional Phenotyping. Pathobiology, 2011, 78, 115-121.	3.8	7
186	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
187	Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome. Blood, 2011, 118, 950-950.	1.4	4
188	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. Blood, 2011, 118, 433-433.	1.4	0
189	A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,. Blood, 2011, 118, 3830-3830.	1.4	0
190	Phospho-SFKs (Y416) As a Potential Predictive Marker for Dasatinib Therapy in B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia,. Blood, 2011, 118, 3727-3727.	1.4	0
191	The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities,. Blood, 2011, 118, 4137-4137.	1.4	0
192	Nonâ€mycosis fungoides cutaneous Tâ€cell lymphoma: reclassification according to the WHOâ€EORTC classification. Journal of Cutaneous Pathology, 2010, 37, 516-524.	1.3	22
193	Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Annals of Oncology, 2010, 21, 1196-1202.	1.2	42
194	Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Annals of Oncology, 2010, 21, 2246-2254.	1.2	56
195	CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma. Blood, 2010, 116, 3098-3098.	1.4	1
196	Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20). Blood, 2010, 116, 427-427.	1.4	10
197	Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2. Blood, 2010, 116, 611-611.	1.4	4
198	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 803-803.	1.4	0

#	Article	IF	CITATIONS
199	Single Nucleotide Polymorphism Array (SNP-A) Genomic Profiling of Mantle Cell Lymphoma (MCL) Against a Large Control Database Reveals Recurring Copy Number Alterations (CNAs) and Copy Neutral Loss of Heterozygosity (CN-LOH). Blood, 2010, 116, 2001-2001.	1.4	0
200	CBL, CBLB, TET2, ASXL1, and IDH1/2 Mutations as Well as Additional Chromosomal Aberrations Constitute Molecular Events Contributing to Malignant Progression In Advanced Philadelphia Chromosome-Positive Disorders Blood, 2010, 116, 3396-3396.	1.4	2
201	Clonotype Switching Indicates Propensity for Clonal Outgrowth From Diverse Components of the T Cell Repertoire In T Cell Large Granular Lymphocyte Leukemia Blood, 2010, 116, 1171-1171.	1.4	0
202	Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia Blood, 2010, 116, 1675-1675.	1.4	0
203	Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. Blood, 2010, 116, 2736-2736.	1.4	0
204	Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leukemia and Lymphoma, 2009, 50, 2005-2012.	1.3	21
205	Quantitative In Situ Detection of Phosphoproteins in Fixed Tissues Using Quantum Dot Technology. Journal of Histochemistry and Cytochemistry, 2009, 57, 701-708.	2.5	19
206	The Role of Biomarkers in the Management of Patients with Lymphoma: Promise Versus Reality. Clinical Lymphoma and Myeloma, 2009, 9, 121-123.	1.4	1
207	T-cell lymphoma in the head and neck? Think about adult T-cell leukemia/lymphoma. Leukemia and Lymphoma, 2009, 50, 150-151.	1.3	4
208	The Leukemias of Mature Lymphocytes. Hematology/Oncology Clinics of North America, 2009, 23, 843-871.	2.2	10
209	TET2 Mutations Are Frequent in RARS-T Blood, 2009, 114, 3794-3794.	1.4	0
210	Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Blood, 2009, 114, 4681-4681.	1.4	0
211	Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leukemia Research, 2008, 32, 275-285.	0.8	39
212	Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leukemia and Lymphoma, 2008, 49, 2081-2090.	1.3	102
213	CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma. Clinical Cancer Research, 2008, 14, 2775-2784.	7.0	491
214	Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment. Leukemia and Lymphoma, 2008, 49, 1668-1680.	1.3	37
215	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. Journal of Clinical Oncology, 2008, 26, 447-454.	1.6	159
216	FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Blood, 2008, 112, 1003-1003.	1.4	4

#	Article	IF	CITATIONS
217	Frequent Detection of C-Cbl Homozygous Mutation in Secondary Myelogeneous Leukemia Transformed from MDS/MPD with Chromosome 11q Uniparental Disomy. Blood, 2008, 112, 851-851.	1.4	1
218	The Myeloid Cell Surface Receptor IREM-1: A Novel Monoclonal Antibody Target for Acute Myeloid Leukemia (AML). Blood, 2008, 112, 2933-2933.	1.4	0
219	Potent Anti-Cancer Activity of Anti-NTB-a Monoclonal Antibodies in Preclinical Leukemia and Lymphoma Models. Blood, 2008, 112, 4975-4975.	1.4	0
220	OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia Blood, 2008, 112, 1486-1486.	1.4	0
221	Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse Blood, 2008, 112, 1482-1482.	1.4	2
222	Are Mast Cells a Biologic Predictor of Outcome in Follicular Lymphoma?. Blood, 2008, 112, 3772-3772.	1.4	2
223	Acquired 1p Uniparental Disomy Is Associated with Biallelic MPL W515L Mutation in RARS-T Blood, 2008, 112, 1643-1643.	1.4	0
224	CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63) Blood, 2008, 112, 1779-1779.	1.4	0
225	CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML. Blood, 2008, 112, 4003-4003.	1.4	6
226	A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML Blood, 2008, 112, 955-955.	1.4	0
227	Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs. Diffuse Large B-Cell Lymphoma Cells. Blood, 2008, 112, 3765-3765.	1.4	0
228	The Ratio of FOXP3+ Regulatory T Cells to Granzyme B+ Cytotoxic T/NK Cells Predicts Prognosis in Classical Hodgkin Lymphoma and Is Independent of bcl-2 and MAL Expression. American Journal of Clinical Pathology, 2007, 128, 958-965.	0.7	106
229	Biologic predictors in follicular lymphoma: Importance of markers of immune response. Leukemia and Lymphoma, 2007, 48, 2403-2411.	1.3	44
230	Phospho-IkappaB Is Abnormally Expressed in Bone Marrow of CMML Patients Blood, 2007, 110, 2450-2450.	1.4	2
231	The Clinicopathologic Spectrum of Posttransplantation Lymphoproliferative Disorders. Archives of Pathology and Laboratory Medicine, 2007, 131, 1209-1218.	2.5	99
232	Detection of Clonal <i>IGH</i> Gene Rearrangements: Summary of Molecular Oncology Surveys of the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2007, 131, 185-189.	2.5	16
233	Histone H4 Acetylation Is Associated with Improved Relapse-Free Survival in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia (ALL) Less Than 60 Years of Age without Poor Risk Cytogenetics Blood, 2007, 110, 2798-2798.	1.4	0
234	CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Blood, 2007, 110, 2839-2839.	1.4	0

#	Article	IF	CITATIONS
235	Dysregulated Signaling Networks in Chronic Myeloproliferative Disorders: Co-Operation of JAK2 and Src Family Kinases (SFK). Blood, 2007, 110, 1539-1539.	1.4	0
236	IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML Blood, 2007, 110, 1792-1792.	1.4	0
237	The Lymphoid Cell Surface Receptor NTB-A: A Novel Monoclonal Antibody Target for Leukemia and Lymphoma Therapeutics Blood, 2007, 110, 4511-4511.	1.4	1
238	Prognostic Value of Tumor-Infiltrating TIA-1+ Cytotoxic T Cells (TIA1-CTCs) and FOXP3+ Regulatory T Cells (Tregs) in Post-Transplant Lymphoproliferative Disorder (PTLD) Following Solid Organ Transplant (SOT) Blood, 2007, 110, 54-54.	1.4	6
239	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 2006, 107, 4207-4213.	1.4	248
240	MAL Is Expressed in a Subset of Hodgkin Lymphoma and Identifies a Population of Patients With Poor Prognosis. American Journal of Clinical Pathology, 2006, 125, 776-782.	0.7	44
241	CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma Blood, 2006, 108, 3457-3457.	1.4	5
242	Increased Tumor Infiltrating FOXP3+ Regulatory T-Cells Are Associated with Improved Survival in Classical Hodgkin Lymphoma Blood, 2006, 108, 2265-2265.	1.4	8
243	Expression of NTB-A in Normal Tissue, Non-Hodgkin Lymphomas and Investigation of Its Potential Therapeutic Impact for Chronic Lymphocytic Leukemia Blood, 2006, 108, 4741-4741.	1.4	0
244	Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL) Blood, 2006, 108, 1846-1846.	1.4	0
245	MAL Is Expressed in a Subset of Hodgkin Lymphoma and Identifies a Population of Patients With Poor Prognosis. American Journal of Clinical Pathology, 2006, 125, 776-782.	0.7	17
246	Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome. Journal of Clinical Oncology, 2005, 23, 3773-3779.	1.6	61
247	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle. Leukemia and Lymphoma, 2005, 46, 1423-1427.	1.3	32
248	Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome Blood, 2005, 106, 369-369.	1.4	1
249	Immunohistochemical Expression of CD10, BCL6, and MUM1 in Primary Nodal Diffuse Large B-Cell Lymphoma: MUM1 Expression Alone (but Not Germinal Center B-Cell Immunophenotype) Is an Independent Prognostic Factor Blood, 2005, 106, 4706-4706.	1.4	0
250	Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leukemia Research, 2004, 28, 845-850.	0.8	26
251	Pathology of Primary Cutaneous B-Cell Lymphomas: Diagnosis and Classification. Clinical Lymphoma and Myeloma, 2004, 5, 89-97.	2.1	14
252	Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders. , 2004, 121, 145-165.		5

#	Article	IF	CITATIONS
253	A Clinicopathologic Evaluation of Follicular Lymphoma Grade 3A Versus Grade 3B Reveals No Survival Differences. Archives of Pathology and Laboratory Medicine, 2004, 128, 863-868.	2.5	26
254	Cyclin D1 Immunohistochemistry Identifies a Subset of Plasma Cell Myeloma with Superior Overall Survival Blood, 2004, 104, 4854-4854.	1.4	0
255	MAL Is Expressed in a Subset of Hodgkin Lymphomas and Identifies a Population of Patients with Poor Prognosis Blood, 2004, 104, 3117-3117.	1.4	8
256	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. British Journal of Haematology, 2003, 120, 1017-1025.	2.5	42
257	Update in the pathologic features of mature B-cell and T/NK-cell leukemias. Seminars in Diagnostic Pathology, 2003, 20, 180-195.	1.5	2
258	Detection of Mature T-Cell Leukemias by Flow Cytometry Using Anti–T-Cell Receptor VβAntibodies. American Journal of Clinical Pathology, 2003, 120, 785-794.	0.7	62
259	Primary Cutaneous Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2002, 117, 574-580.	0.7	44
260	Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features. Journal of Clinical Oncology, 2002, 20, 647-655.	1.6	108
261	Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old infant. Journal of Cutaneous Pathology, 2002, 29, 107-112.	1.3	30
262	Detection of bcl-2/JH Translocation by Polymerase Chain Reaction. Archives of Pathology and Laboratory Medicine, 2002, 126, 902-908.	2.5	14
263	Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: Implications for diagnosis of mycosis fungoides in community clinical practice. Journal of the American Academy of Dermatology, 2001, 45, 405-413.	1.2	47
264	Lymphoma Immunophenotyping: A New Era in Paraffin-Section Immunohistochemistry. Advances in Anatomic Pathology, 2001, 8, 218-239.	4.3	35
265	Angiotropic Lymphoma: An Immunophenotypically and Clinically Heterogeneous Lymphoma. Modern Pathology, 2001, 14, 1147-1156.	5.5	112
266	Towards a Molecular Classification of Hematolymphoid Neoplasms: Where Are We Now? Where Are We Going?. Journal of Histochemistry and Cytochemistry, 2001, 49, 1323-1324.	2.5	4
267	Follicular Lymphoma with Marginal Zone Differentiation: Microdissection Demonstrates the t(14;18) in Both the Follicular and Marginal Zone Components. Modern Pathology, 2001, 14, 191-196.	5.5	37
268	Typical and Atypical Chronic Lymphocytic Leukemia Differ Clinically and Immunophenotypically. American Journal of Clinical Pathology, 2001, 116, 655-664.	0.7	62
269	Use of Novel t(11;14) and t(14;18) Dual-Fusion Fluorescence In Situ Hybridization Probes in the Differential Diagnosis of Lymphomas of Small Lymphocytes. Diagnostic Molecular Pathology, 2001, 10, 214-222.	2.1	32
270	A Practical Approach for Evaluating New Antibodies in the Clinical Immunohistochemistry Laboratory. Archives of Pathology and Laboratory Medicine, 2001, 125, 289-294.	2.5	46

#	Article	IF	CITATIONS
271	Clinicopathologic Reassessment of Primary Cutaneous B-Cell Lymphomas With Immunophenotypic and Molecular Genetic Characterization. American Journal of Surgical Pathology, 2000, 24, 694-702.	3.7	115
272	Biclonal Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2000, 113, 798-804.	0.7	28
273	Usefulness of CD79b Expression in the Diagnosis of B-Cell Chronic Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2000, 113, 805-813.	0.7	34
274	Paroxysmal Nocturnal Hemoglobinuria Testing by Flow Cytometry. American Journal of Clinical Pathology, 2000, 114, 798-806.	0.7	8
275	Mucosa-Associated Lymphoid Tissue-Type Lymphomas Occurring in Post-Transplantation Patients. American Journal of Surgical Pathology, 2000, 24, 100.	3.7	94
276	Immunohistochemical Analysis of CD30-Positive Lymphoproliferative Disorders for Expression of CD95 and CD95L. Modern Pathology, 2000, 13, 446-451.	5.5	9
277	Multiparameter Immunohistochemical Analysis of the Cell Cycle Proteins Cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in Mantle Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2000, 124, 1457-1462.	2.5	29
278	Bcl-6 Protein Expression by Follicle Center Lymphomas: A Marker for Differentiating Follicle Center Lymphomas From Other Low-Grade Lymphoproliferative Disorders. American Journal of Clinical Pathology, 1999, 112, 101-107.	0.7	47
279	Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Modern Pathology, 1998, 11, 1046-51.	5.5	38
280	Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. Journal of Dermatological Science, 1996, 11, 1-9.	1.9	35
281	Detection of immunoglobulin heavy chain gene rearrangement by polymerase chain reaction in chronic active gastritis associated with Helicobacter pylori. Human Pathology, 1996, 27, 290-296.	2.0	72
282	Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1736-1739.	3.6	163
283	Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Modern Pathology, 1995, 8, 817-24.	5.5	20